Advanced search
Add to list

Health state utilities for metastatic breast cancer

(2006) BRITISH JOURNAL OF CANCER. 95(6). p.683-690
Author
Organization
Abstract
The aim of the study was to obtain United Kingdom-based societal preferences for distinct stages of metastatic breast cancer (MBC) and six common toxicities. Health states were developed based on literature review, iterative cycles of interviews and a focus group with clinical experts. They described the burden of progressive, responding and stable disease on treatment; and also febrile neutropenia, stomatitis; diarrhoea/vomiting; fatigue; hand-foot syndrome (grade 3/4 toxicities) and hair loss. One hundred members of the general public rated them using standard gamble to determine health state utility. Data were analysed with a mixed model analysis. The study sample was a good match to the general public of England and Wales by demographics and current quality of life. Stable disease on treatment had a utility value of 0.72, with a corresponding gain of +0.07 following a treatment response and a decline by 0.27 for disease progression. Toxicities lead to declines in utility between 0.10 (diarrhoea/vomiting) and 0.15 (febrile neutropenia). This study underlines the value that society place on the avoidance of disease progression and severe side effects in MBC. This may be the largest preference study in breast cancer designed to survey a representative general public sample.
Keywords
breast cancer, utility, quality of life, standard gamble, QUALITY-OF-LIFE, PHASE-III, DOCETAXEL, CHEMOTHERAPY, PACLITAXEL, THERAPY

Citation

Please use this url to cite or link to this publication:

MLA
Lloyd, A et al. “Health State Utilities for Metastatic Breast Cancer.” BRITISH JOURNAL OF CANCER 95.6 (2006): 683–690. Print.
APA
Lloyd, A, Nafees, B., Narewska, J., Dewilde, S., & Watkins, J. (2006). Health state utilities for metastatic breast cancer. BRITISH JOURNAL OF CANCER, 95(6), 683–690.
Chicago author-date
Lloyd, A, B Nafees, J Narewska, Sarah Dewilde, and J Watkins. 2006. “Health State Utilities for Metastatic Breast Cancer.” British Journal of Cancer 95 (6): 683–690.
Chicago author-date (all authors)
Lloyd, A, B Nafees, J Narewska, Sarah Dewilde, and J Watkins. 2006. “Health State Utilities for Metastatic Breast Cancer.” British Journal of Cancer 95 (6): 683–690.
Vancouver
1.
Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. BRITISH JOURNAL OF CANCER. 2006;95(6):683–90.
IEEE
[1]
A. Lloyd, B. Nafees, J. Narewska, S. Dewilde, and J. Watkins, “Health state utilities for metastatic breast cancer,” BRITISH JOURNAL OF CANCER, vol. 95, no. 6, pp. 683–690, 2006.
@article{8579789,
  abstract     = {The aim of the study was to obtain United Kingdom-based societal preferences for distinct stages of metastatic breast cancer (MBC) and six common toxicities. Health states were developed based on literature review, iterative cycles of interviews and a focus group with clinical experts. They described the burden of progressive, responding and stable disease on treatment; and also febrile neutropenia, stomatitis; diarrhoea/vomiting; fatigue; hand-foot syndrome (grade 3/4 toxicities) and hair loss. One hundred members of the general public rated them using standard gamble to determine health state utility. Data were analysed with a mixed model analysis. The study sample was a good match to the general public of England and Wales by demographics and current quality of life. Stable disease on treatment had a utility value of 0.72, with a corresponding gain of +0.07 following a treatment response and a decline by 0.27 for disease progression. Toxicities lead to declines in utility between 0.10 (diarrhoea/vomiting) and 0.15 (febrile neutropenia). This study underlines the value that society place on the avoidance of disease progression and severe side effects in MBC. This may be the largest preference study in breast cancer designed to survey a representative general public sample.},
  author       = {Lloyd, A and Nafees, B and Narewska, J and Dewilde, Sarah and Watkins, J},
  issn         = {0007-0920},
  journal      = {BRITISH JOURNAL OF CANCER},
  keywords     = {breast cancer,utility,quality of life,standard gamble,QUALITY-OF-LIFE,PHASE-III,DOCETAXEL,CHEMOTHERAPY,PACLITAXEL,THERAPY},
  language     = {eng},
  number       = {6},
  pages        = {683--690},
  title        = {Health state utilities for metastatic breast cancer},
  url          = {http://dx.doi.org/10.1038/sj.bjc.6603326},
  volume       = {95},
  year         = {2006},
}

Altmetric
View in Altmetric
Web of Science
Times cited: